Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Fahad Laghari

Vascular Neurology Tucson, AZ Medical Doctor

NPI 1750810404 CMS profile 9428045

6567 E Carondelet Dr Ste 305, Tucson, AZ 85710

Open in the dashboard

General payments

$15,407

398 records reported · program years 2022–2025

Research payments

$30

Paid to them · 1 record reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fahad Laghari of Tucson, AZ is reported in the CMS Open Payments database as having received $15,407 across 398 general payments and $30 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,121 144
2024 General $6,277 175
2023 General $1,867 78
2023 Research $30 1
2022 General $142 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fahad Laghari
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Fahad Laghari were reported at $7,121. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Fahad Laghari Vascular Neurology median Middle half National median
2019 $0 $263 $102–$1,640 $163
2020 $0 $153 $45–$1,000 $114
2021 $0 $261 $100–$1,355 $132
2022 $142 $242 $87–$1,273 $149
2023 $1,867 $322 $97–$1,266 $160
2024 $6,277 $247 $70–$1,053 $164
2025 $7,121 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Stryker Corporation $8,532 290 payments
  2. Penumbra, Inc. $1,933 7 payments
  3. DePuy Synthes Sales Inc. $1,658 67 payments
  4. Scientia Vascular $893 2 payments
  5. Balt USA, LLC $843 9 payments
  6. Medical Device Business Services, Inc. $417 1 payment
  7. Rapid Medical LTD $359 7 payments
  8. Medtronic, Inc. $239 8 payments
  9. Imperative Care, INc $200 3 payments
  10. MicroVention, Inc. $168 1 payment
  11. Other $164 3 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $10,847 386 payments
  2. Travel and Lodging $3,760 11 payments
  3. Consulting Fee $800 1 payment
Products named General payments · program years 2022–2025
  1. SURPASS EVOLVE $3,788 146 payments
  2. TARGET $3,664 146 payments
  3. AXS VECTA 71 $1,662 70 payments
  4. Penumbra System $1,373 6 payments
  5. EVOLVE $1,306 6 payments
  6. TRUFILL $891 23 payments
  7. Optima Coil System $866 6 payments
  8. TREVO $719 28 payments
  9. CEREPAK UNIFORM $606 23 payments
  10. Indigo System $560 1 payment
  11. Other $3,062 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2022–2025
  1. Sim&Cure Inc $30 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for Neurology: 833

Drug cost

$16,416

Median for Neurology: $202,670

Branded share of claims

66.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 22 $16,308
Atorvastatin Calcium Generic 11 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$15,115

Medicare's payments for the services billed

Medicare patients

109

Average age 76

Services billed

182

71 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Depression 46%
Diabetes 40%
Ischemic heart disease 39%
Atrial fibrillation 39%
Chronic kidney disease 39%
Osteoporosis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record